Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG + Azathioprine vs Basiliximab + MMF in Kidney Transplantation
NCT03789006Phase 4Unknown
- Sponsor
- University of Khartoum
- Start
- Mar 2018
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of antithymocyte globulin rabbit and basiliximab in kidney transplant rejection (2 arms), sponsored by University of Khartoum. Primary endpoints: Incidence of acute rejection at 6 months and One year graft survival at 1 year. Status: unknown.
02
Drugs
antithymocyte globulin rabbitbasiliximab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03789006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03789006.